Business context and reporting period
Filing identity: The supplied filing is iGambit Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012—not a filing identified as Nutex Health Inc. The summary below reflects the filing text.
iGambit’s operating subsidiary, Gotham Innovation Lab, provided media technology products and services to real estate businesses. The company also reported technical consulting revenue. Its former revenue-sharing arrangement with Digi-Data Corporation (DDC) ended February 28, 2011; related balances remained on the balance sheet.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $480,348 | $411,903 |
| Cost of sales | $255,038 | $130,221 |
| Gross profit / margin | $225,310 / 46.9% | $281,682 / 68.4% |
| General and administrative expense | $496,941 | $452,399 |
| Operating loss | $(271,631) | $(170,717) |
| Continuing-operations loss | $(163,535) | $(114,265) |
| Discontinued-operations income | — | $159,785 |
| Net income (loss) | $(163,535) | $45,520 |
| Basic and diluted loss per share | $(0.01) | Continuing operations: $(0.01); total net income per share: $0.00 as reported |
| Operating cash flow | $(4,796) | $(255,377) |
| Ending cash | $216,162 | $356,930 |
At March 31, 2012, total assets were $1,764,982, current assets $1,629,000, total liabilities and current liabilities $325,924, and stockholders’ equity $1,439,058. Working capital was approximately $1.30 million. Current liabilities included $298,359 of accounts payable, a $22,265 related-party note, and a $5,300 stockholder loan; the company reported no long-term liabilities. Cash declined $8,638 from year-end.
Notable asset balances included $434,512 of notes receivable from Allied Airbus, all past due, and $420,590 of assets from discontinued operations, consisting of DDC-related receivables. Deferred tax assets were $285,441. These balances are not equivalent to immediately available cash.
Material changes versus the prior period
- Revenue rose 16.6%, but cost of sales nearly doubled, reducing gross profit by $56,372 and gross margin by about 21.5 percentage points.
- G&A expense increased $44,542. Management attributed the increase mainly to SEC registration-statement professional costs and Gotham operating costs; payroll was the largest listed expense.
- The company moved from $45,520 net income to a $163,535 net loss. The prior-year quarter included $159,785 of income from discontinued operations; there was none in 2012 after the DDC agreement ended.
- Operating cash use improved substantially year over year, but Q1 2012 operating cash flow included $150,000 from a decrease in discontinued-operations receivables. Continuing-operations operating cash flow was negative $154,796.
- Total assets fell $126,196 from December 31, 2011, while liabilities increased $37,339; equity declined $163,535.
Outlook, risks, contingencies, and unusual items
- Management said it intends to grow Gotham through marketing and potential new clients, and to pursue acquisitions or partnerships. Several proposals were outstanding, but no quantified forecast or formal financial guidance was provided.
- Management said it believed existing capital was sufficient for current operations and expected cash and liquidity to increase, while acknowledging that expansion and acquisitions could require private-market financing and that financing or execution was not assured.
- The $434,512 Allied Airbus notes bear 6% interest, were past due at quarter-end, and are subject to collection litigation. The defendants and guarantors filed a counterclaim alleging fraud and violations of Florida consumer-protection law, including allegations relating to a claimed $1.5 million loan commitment.
- Three customers represented approximately 65% of Gotham’s Q1 sales, creating customer concentration risk.
- The company entered a five-year executive-office lease in February 2012. Disclosed future minimum payments totaled $89,100 through 2016.
- Management reported no goodwill impairment in Q1, although it did not perform a new impairment study during the quarter. The filing cautions that results may fluctuate and identifies competition, regulation, and technology change as risks.
- The filing reported disclosure controls as effective as of March 31, 2012, and no material Q1 changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the source is iGambit Inc., not Nutex Health Inc.; verify that this is the intended filing before relying on the figures.
- Assess collectability and timing of the past-due $434,512 Allied notes and the $420,590 DDC-related discontinued-operations receivable, including the status and potential outcome of the Allied litigation and counterclaim.
- Reconcile the filing’s explanations of cash flows and working-capital movements with the financial statements; the MD&A’s prepaid-expense change differs from the statement of cash flows.
- Evaluate Gotham’s gross-margin decline, customer concentration, and ability to cover corporate expenses from continuing operations without discontinued-operation cash receipts.
- Review the planned funding needs and feasibility of management’s expansion and acquisition strategy; no specific forecast or committed financing is disclosed.